DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
RVTY logo

Revvity, Inc. Stock Price

NYSE:RVTY Community·US$13.8b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 16 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

RVTY Share Price Performance

US$120.94
35.26 (41.15%)
​
US$121.07
Fair Value
US$120.94
35.26 (41.15%)
Fairly Valued intrinsic discount
US$121.07
Fair Value
Price US$120.94
AnalystConsensusTarget US$121.07
AnalystLowTarget US$100.00
AnalystHighTarget US$157.61
Wed, 5 Aug 26
Fair ValueUS$121.07
Share Pricen/a

RVTY Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$121.07 Fairly Valued intrinsic discount

RVTY: Operating Margins And Buyback Plan Will Drive Share Recovery Ahead

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$100 20.9% overvalued intrinsic discount

Regulatory Shifts Will Pressure Diagnostics Yet Spur Measured Turnaround

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$157.61 23.3% undervalued intrinsic discount

Genomics And Automation Will Expand Diagnostics In Aging Populations

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
RVTY logo
Revvity
23.3% undervalued intrinsic discount
Updated

Genomics And Automation Will Expand Diagnostics In Aging Populations

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 4 Sep
Read Narrative
RVTY logo
Revvity
Fairly Valued intrinsic discount

RVTY: Operating Margins And Buyback Plan Will Drive Share Recovery Ahead

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 5 Aug
Read Narrative
RVTY logo
Revvity
20.9% overvalued intrinsic discount

Regulatory Shifts Will Pressure Diagnostics Yet Spur Measured Turnaround

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 20 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
RVTY logo

RVTY: AI Screening Demand And Sector Recovery Will Support Future Upside

Fair Value: US$157.61 23.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
RVTY logo

RVTY: Elevated Multiple And Sector Headwinds Will Challenge 2026 Outlook

Fair Value: US$100 20.9% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
RVTY logo

RVTY: AI R&D Tools And Sector Backdrop Will Shape Future Earnings Power

Fair Value: US$121.07 Fairly Valued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Adequate balance sheet with moderate growth potential.

1 Risk
2 Rewards
View Full Analysis

Revvity, Inc. Key Details

US$2.9b

Revenue

US$1.3b

Cost of Revenue

US$1.6b

Gross Profit

US$1.4b

Other Expenses

US$237.4m

Earnings

Last Reported Earnings
Jul 05, 2026
Next Reporting Earnings
n/a
2.13
54.98%
8.15%
44.3%
View Full Analysis

About RVTY

Founded
1937
Employees
11000
CEO
Prahlad Singh
WebsiteView website
www.revvity.com

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Recent RVTY News & Updates

User avatar
Narrative Update • Sep 04

RVTY: AI Screening Demand And Sector Recovery Will Support Future Upside

Analysts have raised their implied fair value for Revvity from about $143 to about $158, reflecting updated views on revenue growth, margins, and P/E assumptions in light of higher Street price targets and commentary on improving demand and AI-driven screening opportunities. Analyst Commentary Recent Street research on Revvity points to a more constructive setup in the stock, with several bullish analysts lifting price targets and highlighting improving demand trends in key end markets.
User avatar
Narrative Update • Aug 20

RVTY: Elevated Multiple And Sector Headwinds Will Challenge 2026 Outlook

Analysts have lifted the fair value estimate for Revvity stock from $90 to $100, pointing to updated price targets in the $115 to $130 range and research that highlights steady sector trends, healthier capital spending, and a higher assumed future P/E multiple, despite more conservative profit margin assumptions. Analyst Commentary on Revvity Recent Street research on Revvity points to a mix of optimism and caution.

Recent updates

No updates

Revvity, Inc. Competitors

REGN logo

Regeneron Pharmaceuticals

Symbol: NasdaqGS:REGN
Market cap: US$80.6b
MRNA logo

Moderna

Symbol: NasdaqGS:MRNA
Market cap: US$54.1b
NTRA logo

Natera

Symbol: NasdaqGS:NTRA
Market cap: US$47.6b
RVMD logo

Revolution Medicines

Symbol: NasdaqGS:RVMD
Market cap: US$44.5b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide